Post hoc analysis of two trials: of 122 Crohn's disease week-12 non-responders to upadacitinib with data, 52.5% responded by week 24. Those without a ≥20% fall in MM-SES-CD by week 12 were less likely to respond (33.3% vs 61.5%; aOR 0.22).
Secondary analysisn = 665
Wong et al. Week 12 Reduction in Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Is Predictive of Delayed Response to Upadacitinib in Crohn's Disease